Intracellular zinc increase inhibits p53-/- pancreatic adenocarcinoma cell growth by ROS/AIF-mediated apoptosis

32Citations
Citations of this article
31Readers
Mendeley users who have this article in their library.

Abstract

We show that treatment with non-toxic doses of zinc in association to the ionophore compound pyrrolidine dithiocarbamate (PDTC) inhibits p53-/- pancreatic cancer cell growth much more efficiently than gemcitabine, the gold standard chemotherapeutic agent for pancreatic cancer. Both the metal chelator N,N,N′,N′-tetrakis(2-pyridylmethyl)ethylenediamine and the radical scavenger N-acetyl-l-cysteine are able to recover cell growth inhibition by Zn/PDTC, demonstrating that this effect depends on the increased levels of intracellular zinc and of reactive oxygen species (ROS). Zn/PDTC treatment induces a strong apoptotic cell death that is associated to ROS-dependent nuclear translocation of the mitochondrial factor AIF, but not to the regulation of apoptotic genes and caspase activation. Primary fibroblasts are more resistant than pancreatic cancer cells to Zn/PDTC treatment and exhibit a lower basal and Zn/PDTC-induced enhancement of intracellular zinc. We show that Zn/PDTC induces p53 proteasomal degradation and that the proteasome inhibitor MG132 further increases fibroblast growth inhibition by Zn/PDTC, suggesting that p53 degradation plays an important role in fibroblast resistance to Zn/PDTC. © 2008 Elsevier B.V. All rights reserved.

Cite

CITATION STYLE

APA

Donadelli, M., Dalla Pozza, E., Scupoli, M. T., Costanzo, C., Scarpa, A., & Palmieri, M. (2009). Intracellular zinc increase inhibits p53-/- pancreatic adenocarcinoma cell growth by ROS/AIF-mediated apoptosis. Biochimica et Biophysica Acta - Molecular Cell Research, 1793(2), 273–280. https://doi.org/10.1016/j.bbamcr.2008.09.010

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free